Imatinib Mesylate Resistance in a Chronic Myeloid Leukemia Patient with a Novel e8a2 BCR-ABL Transcript Variant

By  

Acta Haematologica, Vol. 120, Iss. 3, 2008-11 ,pp. : 146-149

Karger

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination of EUTOS score and 3‐month BCR‐ABL transcript level identifies a group of good‐risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E135-E137

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases

By  

Acta Haematologica, Vol. 122, Iss. 1, 2009-07 ,pp. : 11-16

Karger

Access to resources Recommend Favorite

Natural History of Southeast Asian Chronic Myeloid Leukemia Patients with Different BCR-ABL Gene Variants

By  

Acta Haematologica, Vol. 116, Iss. 2, 2006-08 ,pp. : 114-119

Karger

Access to resources Recommend Favorite